Jacek Pinski

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.”.

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5506

N/A

0DataRank · unranked

4 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +14 more

Phase II trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.94

N/A

0DataRank · unranked

3 citations

David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn, Olga Castellanos +3 more

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3587

N/A

0DataRank · unranked

34 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +16 more

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

Cancer Chemotherapy and Pharmacology(2021)10.1007/s00280-020-04224-8

N/A

0DataRank · unranked

22 citations

Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos +6 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5080

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek Pinski +13 more